Related Experiment Videos
Reversible monoamine oxidase-A inhibitors in panic disorder
D Bakish1, B M Saxena, R Bowen
1University of Ottawa at Royal Ottawa Hospital, Ontario, Canada.
Clinical Neuropharmacology
|January 1, 1993
Summary
New reversible MAO-A inhibitors like brofaromine offer effective panic disorder treatment with fewer side effects than older drugs. This study found brofaromine comparable to clomipramine in efficacy and safety for panic disorder with or without agoraphobia.
Area of Science:
- Psychiatry
- Pharmacology
- Clinical Trials
Background:
- Monoamine oxidase (MAO) inhibitors are effective for panic disorder but have significant adverse reactions.
- Selective and reversible MAO-A inhibitors, such as brofaromine and moclobemide, offer improved tolerability and fewer interactions.
- Dietary restrictions and drug interactions are concerns with traditional MAO inhibitors.
Purpose of the Study:
- To compare the efficacy and safety of brofaromine versus clomipramine in patients with panic disorder.
- To evaluate brofaromine as a novel treatment option for panic disorder with or without agoraphobia.
Main Methods:
- A randomized, double-blind, 8-week clinical trial.
- Comparison of brofaromine with clomipramine in patients diagnosed with panic disorder.
- Assessment of panic attack frequency and other efficacy parameters.
Main Results:
- Both brofaromine and clomipramine demonstrated significant and comparable reductions in panic attack frequency.
- Treatment groups showed equal effectiveness across all measured parameters.
- Observed side effects were consistent with the known profiles of the respective drug classes.
Conclusions:
- Brofaromine is an effective and well-tolerated treatment for panic disorder, comparable to clomipramine.
- Reversible MAO-A inhibitors represent a promising advancement in panic disorder pharmacotherapy.
- Further clinical trials are warranted to fully establish the role of brofaromine.